QualTek Molecular Laboratories
QualTek will be exhibiting at Cambridge Healthtech Institute’s 11th Annual Biomarkers & Diagnostics World Congress 2015, May 5-7, 2015 | Loews Philadelphia Hotel | Philadelphia, PA. We hope to see you there!
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
QualTek’s recent study agreement with Corcept Therapeutics has resulted in a manuscript co-authored by QualTek personnel and published in Cancer Management and Research. The manuscript details QualTek’s development and validation of an IHC assay for Glucocorticoid Receptor which is currently being utilized in clinical trials of mifepristone, a GR antagonist, in patients with Triple Negative Breast Cancer.
The PD-L1 IHC assay, reported in the following Pembrolizumab publications, was
developed and validated by QualTek.
QualTek is proud to share our publication, together with Merck and Co, Inc. scientists
Detailing the development of the prototype PD-L1 assay which we have extensively
tested for various clinical studies for Keytruda® (Pembrolizumab).